• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Femasys Inc.

    3/27/25 9:33:09 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care
    Get the next $FEMY alert in real time by email
    S-8 1 ef20045975_s8.htm S-8
    As filed with the Securities and Exchange Commission on March 27, 2025

    Registration No. 333-

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549



    FORM S-8

    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933



    Femasys Inc.
    (Exact name of registrant as specified in its charter)

    Delaware
     
    11-3713499
    (State or other jurisdiction of incorporation or organization)
     
    (I.R.S. Employer Identification No.)

    3950 Johns Creek Court, Suite 100
    Suwanee, Georgia 30024
    (Address of principal executive offices) (Zip Code)



    FEMASYS INC. 2021 EQUITY INCENTIVE PLAN
    FEMASYS INC. EMPLOYEE STOCK PURCHASE PLAN
    (Full title of the Plans)



    Kathy Lee-Sepsick
    President and Chief Executive Officer
    3950 Johns Creek Court, Suite 100
    Suwanee, Georgia 30024
    (770) 500-3910
    (Name, address, including zip code, and telephone number, including area code, of agent for service)



    With a copy to:

    David S. Rosenthal, Esq.
    Anna Tomczyk Esq.
    Dechert LLP
    1095 Avenue of Americas
    New York, New York 10036
    (212) 698-3616



    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer ☐
    Accelerated filer ☐
    Non-accelerated filer ☒
    Smaller reporting company ☒
     
    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒



    REGISTRATION OF ADDITIONAL SHARES
    PURSUANT TO GENERAL INSTRUCTION E

    Pursuant to General Instruction E of Form S-8, the Registrant is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register 934,237 additional shares of common stock under the Femasys Inc. 2021 Equity Incentive Plan and 233,559 additional shares of common stock under the Femasys Inc. Employee Stock Purchase Plan pursuant to the provisions of those plans providing for an automatic increase in the number of shares reserved for issuance under such plans. This Registration Statement hereby incorporates by reference the contents of the Registrant’s registration statements on Form S-8 filed with the Commission on June 22, 2021 (Registration No. 333-257284), March 24, 2022 (Registration No. 333-263833), April 5, 2023 (Registration No. 333-271139) and April 5, 2024 (Registration No. 333-278541).

    Item 8.
    Exhibits.

    EXHIBIT INDEX

    Exhibit Number
     
    Exhibit Description
         
    5.1*
     
    Opinion of Dechert LLP.
         
    23.1*
     
    Consent of Dechert LLP (included in Exhibit 5.1).
         
    23.2*
     
    Consent of KPMG LLP.
         
    24.1*
     
    Power of Attorney (included on signature page).
         
    99.1
     
    Femasys Inc. 2021 Equity Incentive Plan, and forms of agreements thereunder (Incorporated by reference to Exhibit 10.3 of the Registrant’s Registration Statement on Form S-1 (File No. 333-256156) filed May 14, 2021).
         
    99.2
     
    Femasys Inc. 2021 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.4 of the Registrant’s Registration Statement on Form S-1 (File No. 333-256156) filed May 14, 2021).
         
    107*
     
    Filing Fee Table

    *
    Filed herewith


    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Suwanee, State of Georgia on March 27, 2025.

    FEMASYS INC.
     
    By:
    /s/ Kathy Lee-Sepsick
     
    Kathy Lee-Sepsick
     
    Chief Executive Officer and President


    POWER OF ATTORNEY

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Kathy Lee-Sepsick and Dov Elefant, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to sign any Registration Statement for the same offering covered by this Registration Statement that is to be effective upon filing pursuant to Rule 462(b) promulgated under the Securities Act, and all post-effective amendments thereto, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities held and on the dates indicated.

    Signature
     
    Title
     
    Date
             
    /s/ Kathy Lee-Sepsick
     
    President, Chief Executive Officer and Director (principal executive officer)
     
    March 27, 2025
    Kathy Lee-Sepsick
           
             
    /s/ Dov Elefant
     
    Chief Financial Officer (principal financial and accounting officer)
     
    March 27, 2025
    Dov Elefant
           
             
    /s/ Charles Larsen
     
    Chair of the Board of Directors
     
    March 27, 2025
    Charles Larsen
           
             
    /s/ Alistair Milnes
     
    Director
     
    March 27, 2025
    Alistair Milnes
           
             
    /s/ Joshua Silverman
     
    Director
     
    March 27, 2025
    Joshua Silverman
           
             
    /s/ Edward Uzialko, Jr.
     
    Director
     
    March 27, 2025
    Edward Uzialko, Jr.
           



    Get the next $FEMY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FEMY

    DatePrice TargetRatingAnalyst
    7/13/2021$18.00Buy
    JonesTrading
    7/13/2021$25.00Buy
    Chardan Capital
    More analyst ratings

    $FEMY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

      -- Femasys continues to expand access and market share for its first-line infertility treatment option, FemaSeed® -- ATLANTA, June 11, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products announces a partnership with Carolinas Fertility Institute (CFI), one of America's best fertility clinics. Carolinas Fertility Institute will provide the Company's FemaSeed® intratubal insemination product as an infertility treatment option to patients throughout its network in North Carolina. "Our partnership

      6/11/25 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million

      ATLANTA, May 30, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY) (the "Company" or "Femasys"), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a public offering price of $0.85 per share and a separate concurrent private placement of 1,686,275 shares of its common stock at a price of $0.85 per share sold to certain existing institutional stockholders of Femasys and a price of $1.02 per share to certain of its directors and officers. The gros

      5/30/25 8:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

      ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY) (the "Company" or "Femasys"), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Femasys expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. In addition, certain existing institutional stockholders of Femasys and certain of its directors and officers have indicated

      5/29/25 4:23:17 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JonesTrading initiated coverage on Femasys with a new price target

      JonesTrading initiated coverage of Femasys with a rating of Buy and set a new price target of $18.00

      7/13/21 11:41:28 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Chardan Capital initiated coverage on Femasys with a new price target

      Chardan Capital initiated coverage of Femasys with a rating of Buy and set a new price target of $25.00

      7/13/21 8:04:59 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Elefant Dov

      4 - FEMASYS INC (0001339005) (Issuer)

      6/4/25 3:51:39 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Chief Operating Officer Currie Daniel Scott increased direct ownership by 29% to 86,275 units (SEC Form 4)

      4 - FEMASYS INC (0001339005) (Issuer)

      6/4/25 3:51:42 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Larsen Charles

      4 - FEMASYS INC (0001339005) (Issuer)

      6/4/25 3:51:45 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Leadership Updates

    Live Leadership Updates

    See more
    • Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

      ATLANTA, March 21, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing the significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, invites investors to join management in a Fireside Chat with Jones Trading Analyst Catherine Novack to discuss the current treatment landscape for infertility treatment in women. Those interested in attending the event, which will be held virtually TODAY, March 21, 2024 at 1PM ET, may register here. Femasys CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu, M.D. will focus on the current treatment options in the inf

      3/21/24 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

      -- Seasoned sales and marketing executive with 25 years of experience leading public and private healthcare companies throughout various stages of commercialization will lead commercial launch of FemaSeed -- ATLANTA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the appointment of Richard Spector to chief commercial officer (CCO), effective February 2024. Mr. Spector has 25 years of experience spanning a contin

      2/6/24 8:30:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer

      ATLANTA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced the appointment of James Liu, M.D., as Chief Medical Officer. Dr. Liu joins Femasys as the company accelerates commercialization of its product pipeline, including a new therapeutic for artificial insemination, FemaSeed®. "With an exciting product pipeline and a culture focused on execution of the development and commercialization of differentiated women's

      11/30/23 8:30:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    SEC Filings

    See more
    • SEC Form D filed by Femasys Inc.

      D - FEMASYS INC (0001339005) (Filer)

      6/10/25 1:30:16 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - FEMASYS INC (0001339005) (Filer)

      6/2/25 7:29:23 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • SEC Form 424B5 filed by Femasys Inc.

      424B5 - FEMASYS INC (0001339005) (Filer)

      6/2/25 7:25:56 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Femasys Inc.

      SC 13D - FEMASYS INC (0001339005) (Subject)

      11/22/23 4:00:15 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care

    $FEMY
    Financials

    Live finance-specific insights

    See more
    • Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

      -- Company delivers on mission to transform women's health with innovative solutions, including FemaSeed® for first-line infertility treatment and FemBloc® non-surgical permanent birth control (full system approval pending in Europe) -- ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the quarter ended March 31, 2025 and provides a corporate update. Corporate Highlights from 1Q 2025 to date Announced FemBloc permanent birth control delivery syste

      5/8/25 5:01:00 PM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

      -- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain -- ATLANTA, March 27, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the year ended December 31, 2024 and provides a corporate update. Corporate Highlights from 4Q 2024 to date Announced FemBloc® permanent birth control (delivery system) approval in Europe; FemBloc blended polymer component s

      3/27/25 9:00:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care
    • Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

      ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended September 30, 2024 and provides a corporate update. Corporate Highlights from 3Q 2024 to date Announced partnership with Boston IVF, prominent network of fertility centers, to offer FemaSeed®Announced the onboarding of the first infertility medical clinic customers to offer FemaSeed infertility treatment to patients in California and FloridaAnnounced strategic distributi

      11/12/24 8:30:00 AM ET
      $FEMY
      Medical/Dental Instruments
      Health Care